RxDoctor Payments Data

Edith Graves, MD

Hematology & Oncology · Opelika, ALNPI 1396826129

Payments from drug & device makers

$1,456in general payments, 2019–2025

Across 78 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$126
  • Gilead$112
  • AbbVie$105
  • Amgen$96
  • Bristol Myers Squibb$92
  • Johnson & Johnson$91
  • plus $833 from 23 others

What the payments were for

  • Food & beverage$1,44499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,456 in reported general payments places this provider in the 15th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama

Medicare billing

Part B allowed, 2024
$29,445
Medicare patients
216
Services billed
442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide47$639,928
ImbruvicaIbrutinib26$440,615
IbrancePalbociclib28$422,243
CalquenceAcalabrutinib Maleate24$364,054
Lenalidomide16$218,978
VenclextaVenetoclax11$169,207
CreonLipase/Protease/Amylase17$31,228
Letrozole284$6,398
Anastrozole146$3,990
Tamoxifen Citrate40$1,171
ValacyclovirValacyclovir Hcl32$1,059
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$1,029
Morphine Sulfate ErMorphine Sulfate24$1,009
Potassium Chloride23$847
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen48$490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$20$639,92847 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$71$440,61526 claims
PfizerIbrance$126$422,24328 claims
AstraZenecaCalquence$51$364,05424 claims
AbbVieVenclexta, Creon$105$200,43528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 177 hematology & oncology providers in Alabama.

Other hematology & oncology in Opelika

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →